CPC 405

Drug Profile

CPC 405

Latest Information Update: 17 Apr 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Questcor Pharmaceuticals
  • Class Anti-ischaemics; Cytoprotectives; Small molecules
  • Mechanism of Action Adenosine deaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral ischaemia; Ischaemic heart disorders

Most Recent Events

  • 17 Apr 2001 Discontinued-Preclinical for Cerebral ischaemia in USA (Unknown route)
  • 17 Apr 2001 Discontinued-Preclinical for Ischaemic heart disorders in USA (Unknown route)
  • 20 Dec 1999 Cypros Pharmaceutical has merged with RiboGene to form Questcor Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top